
Work Here?
Company Historically Provides H1B Sponsorship
Illumina provides integrated sequencing platforms and related consumables for analyzing genetic variation and biological function. Its instruments range from high-throughput NovaSeq systems to benchtop MiSeq/iSeq units, all built on sequencing-by-synthesis technology acquired from Solexa. Revenue comes from instrument sales plus a recurring stream of consumables, reagents, library preparation kits, and services. The company differentiates itself with a broad end-to-end ecosystem and strategic acquisitions (Solexa, GRAIL, SomaLogic) that expand capabilities into multiomics and clinical diagnostics.
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1998
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$2.1B
Above
Industry Average
Funded Over
5 Rounds
Professional Development Budget
Illumina reported second-quarter revenues of $1.16 billion, marking a 9.4% year-on-year increase that exceeded analyst expectations by 2.5%. The DNA sequencing and microarray technology company delivered strong organic revenue performance and raised its full-year earnings guidance. Chief executive Jacob Thaysen attributed the results to growing momentum in sequencing-intensive applications among clinical customers. The company increased its revenue and earnings guidance for the year based on this performance. Illumina's shares rose 10% following the earnings announcement and currently trade at $225.55. The results came as part of a strong second quarter for the life sciences tools and services sector overall, with the 20 tracked stocks in the group beating revenue estimates by 2.6% on average.
Illumina has entered into a $1 billion credit facility with Bank of America serving as administrative agent. The genomics company announced the agreement after market close on Thursday. The credit facility also includes an underwriting agreement for a note offering, though specific terms were not disclosed in the announcement.
Illumina has filed to issue senior notes maturing in 2029, expecting to raise approximately $750 million. The unsecured notes will rank equally with the company's other unsecured debt and feature a yield near the current US Treasury benchmark. Proceeds will primarily repay an earlier 4.65% note due in September 2026. By extinguishing higher-cost debt, Illumina aims to reduce its interest burden and improve its debt-to-equity ratio. The company expects its weighted average cost of capital to decrease from 5.8% to an estimated 4.9%. The notes include a make-whole redemption clause and a change-of-control provision requiring Illumina to purchase notes at 101% of principal plus interest. Illumina holds Moody's A-3 and S&P A- credit ratings. The refinancing supports ongoing investment in next-generation sequencing platforms, data analytics, and cloud-based services whilst enhancing financial flexibility for strategic acquisitions and R&D funding.
Illumina reported second quarter 2026 revenue of $1.16 billion, up 9.5% from the prior year period. The San Diego-based genomics company posted GAAP diluted earnings per share of $1.35 and non-GAAP diluted earnings per share of $1.31. Chief executive Jacob Thaysen said momentum built through the first half of 2026 as the company's technology enabled clinical customers to expand sequencing-intensive applications. He noted that demand for NovaSeq X remains high. Based on this performance, Illumina raised its full-year 2026 revenue guidance to $4.60-$4.64 billion, up from prior guidance of $4.52-$4.62 billion. The company increased its non-GAAP diluted earnings per share guidance to $5.30-$5.40, versus prior guidance of $5.15-$5.30.
Scale AI turns to Google Cloud veteran to steer post-wang era. Scale AI has appointed Francis deSouza, former COO of Google Cloud and ex-CEO of Illumina, as its new CEO effective August 10. Succeeding interim leader Jason Droege, deSouza brings deep enterprise experience to help the company expand beyond data labeling into full AI applications for businesses and governments. The move comes after founder Alexandr Wang joined Meta last year. Thursday, July 30, 2026 Scale AI just named a battle-tested enterprise operator as its new chief executive. Francis deSouza, who spent years as chief operating officer at Google Cloud, will take the helm on August 10. The move signals a clear shift for the data-labeling powerhouse that once defined itself through breakneck growth under a twentysomething founder. Alexandr Wang built Scale from a Y Combinator idea into a company valued at tens of billions. He left last year to lead Meta's superintelligence push after the social media giant poured $14.3 billion into a minority stake. Wang's departure left a leadership vacuum. Jason Droege stepped in as interim CEO. Now deSouza arrives with more than three decades of experience selling complex technology to big organizations. His track record stands out. As chief executive of Illumina, deSouza expanded the gene-sequencing firm into more than 150 countries and drove annual revenue past $4.5 billion. Before that he held the presidency at Symantec. He even founded two companies that larger players acquired, one by Microsoft and another by Symantec itself. The man knows how to scale operations and close deals with cautious buyers. Yahoo Finance first reported the appointment Thursday morning. Scale needs exactly that kind of steady hand. The company still dominates the market for high-quality training data that powers frontier models at OpenAI, Anthropic and others. Yet its ambitions have broadened. It now sells complete AI applications aimed at enterprises and governments. New customers include BP and the Mayo Clinic. Government contracts have grown too. Revenue projections for 2026 now top $1 billion, according to a person familiar with the figures who spoke on condition of anonymity. But success in this next phase demands something different from the early days. Data labeling once relied on armies of human annotators. Today the work mixes automation, expert review and sophisticated evaluation frameworks. Enterprises want solutions that drop straight into their existing workflows. Governments demand ironclad security and compliance. DeSouza's time at Google Cloud exposed him to both worlds. He helped sell cloud infrastructure to skeptical chief information officers while navigating the regulatory maze that surrounds large technology contracts. And the timing feels deliberate. Meta's investment last summer rattled the industry. Google and OpenAI reportedly walked away from major data deals with Scale to avoid feeding a competitor. The loss stung. Yet Scale kept its independence. Interim CEO Droege emphasized that point in a blog post last year, promising the company would chart its own course. He will now spend the coming months guiding deSouza through the transition. DeSouza inherits a firm transformed by the AI boom. What began as a service for self-driving car companies grew into the invisible backbone of modern model development. Every major lab depends on clean, accurately labeled data. Scale's evaluation platforms help teams measure whether their latest model actually improved. That combination of data and judgment has proven hard to replicate. Still, competition intensifies. New entrants promise automated labeling at lower cost. Hyperscalers build internal tools to reduce reliance on outside providers. Chinese labs race ahead on their own data pipelines. Scale must defend its lead while expanding into finished applications. The applications business, in particular, represents both opportunity and risk. Enterprises pay premium prices for tools that solve concrete problems. They also expect vendors to shoulder liability when those tools fail. DeSouza's enterprise DNA could prove decisive here. Illumina sold sophisticated instruments to research labs and hospitals. The sales cycles stretched long. Buyers scrutinized every claim about accuracy and reliability. Those same buyers now evaluate AI systems. They worry about hallucinations, bias and brittleness in high-stakes settings. A CEO who has closed those deals before brings credibility that pure AI founders sometimes lack. His MIT degrees in electrical engineering and computer science don't hurt either. Technical fluency helps when board discussions turn to model architectures or evaluation methodologies. Yet deSouza's real strength lies in execution. He grew businesses. He integrated acquisitions. He managed thousands of employees across continents. Scale, despite its high valuation, remains a company of several thousand people wrestling with the messy realities of human-in-the-loop AI. The hire also reflects broader trends rippling through the industry. Talent wars have escalated. Microsoft poached more than 20 researchers from Google DeepMind in recent months. OpenAI lured key architects away from the same lab. Meta's aggressive recruiting, including Wang himself, has redrawn org charts across Silicon Valley. In this environment, operational experience commands a fresh premium. Building models grabs headlines. Shipping reliable products to paying customers pays the bills. Scale's pivot toward applications mirrors that reality. Pure data providers face margin pressure as automation improves. Full-stack offerings command higher multiples. The company now positions itself as a partner for organizations that want to deploy AI without assembling their own data flywheels. Recent wins with healthcare and energy giants suggest the message resonates. But execution will decide everything. DeSouza must integrate with a culture shaped by Wang's intensity. He must maintain relationships with labs that may view Meta's stake warily. He must accelerate growth without sacrificing the quality that built Scale's reputation. Droege's support during the handover should ease some friction. The interim leader knows the organization intimately after steering it through the post-Wang transition. Industry watchers see the appointment as pragmatic. "Scale needs someone who can talk to Fortune 500 CIOs in their own language," one venture investor said, requesting anonymity to speak freely about a portfolio company. DeSouza speaks that language fluently. His Google Cloud tenure taught him how decisions get made inside large organizations adopting new technology. Those lessons transfer directly to AI sales. The broader context matters too. AI adoption inside enterprises has lagged the hype. Many pilots never reach production. Companies cite integration challenges, unclear return on investment and governance gaps. Scale's new applications aim to close those gaps with pre-built solutions backed by its data expertise. Success could open a massive market. Failure would leave the company exposed as just another data vendor in a commoditizing field. DeSouza starts with advantages. Scale enjoys strong brand recognition among AI researchers. Its evaluation tools have become industry standard in some domains. The Meta investment provides a deep-pocketed partner, even if it complicates other relationships. And the market still hungers for trustworthy AI infrastructure. Governments in particular are pouring money into domestic capabilities. Yet risks abound. Geopolitical tensions could restrict data flows or talent movement. Model developers may invest more heavily in synthetic data to reduce human labeling needs. Regulatory scrutiny of AI supply chains is rising. A new CEO must track all these forces while running day-to-day operations. For now the focus stays practical. DeSouza will spend his first weeks meeting customers, reviewing product roadmaps and assessing the team's strengths. He brings fresh eyes to a company that has known only hypergrowth. That perspective could prove valuable as Scale matures. The appointment also closes a chapter. Wang's exit to Meta marked the end of Scale's founder-led era. Droege kept the lights on and momentum intact. DeSouza now assumes responsibility for the next leg of the journey, one defined less by rapid experimentation and more by disciplined expansion. The choice of a seasoned operator over another flashy AI personality speaks volumes about where the company believes its future lies. Success won't come from charisma alone. It will come from consistent delivery, smart hiring and the ability to translate AI capabilities into measurable business outcomes. DeSouza has done versions of that before. The question is whether he can repeat the feat in an industry that moves faster than anything he has seen. Scale's customers will watch closely. So will its competitors. And so will the labs that still depend on its data pipelines. The stakes have never been higher. But then, Francis deSouza has never been one to shy from big challenges. His career suggests he prefers them. Subscribe for Updates The CEOTrends Email Newsletter is a must-read for forward-thinking CEOs. Stay informed on the latest leadership strategies, market trends, and tech innovations shaping the future of business.
Find jobs on Simplify and start your career today
Industries
Data & Analytics
Biotechnology
Healthcare
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
San Diego, California
Founded
1998
Find jobs on Simplify and start your career today